Asked by: Carla Lockhart (Democratic Unionist Party - Upper Bann)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent steps he has taken to implement the National Suicide Prevention Plan; and what further steps he is taking to help tackle suicide rates.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Suicide Prevention Strategy for England, published in 2023, identifies eight priority groups for targeted and tailored support at a national level. The strategy also identifies key risk factors for suicide, providing an opportunity for effective early intervention.
The purpose of the Suicide Prevention Strategy is to set out our aims to prevent suicide through action by working across Government and other organisations. One of the key visions of the strategy is to reduce stigma surrounding suicide and mental health, so people feel able to seek help, including through the routes that work best for them. This includes raising awareness that no suicide is inevitable.
NHS England published Staying safe from suicide: Best practice guidance for safety assessment, formulation and management to support the Government’s work to reduce suicide and improve mental health services. The guidance requires all mental health practitioners to align their practice to the latest evidence in suicide prevention, and is available at the following link:
https://www.england.nhs.uk/publication/staying-safe-from-suicide/
The NHS England Medium Term Planning Framework states that in 2026/27, all integrated care boards must ensure mental health practitioners across all providers undertake training and deliver care in line with the guidance.
The 10-Year Health Plan sets out ambitious plans to boost mental health support across the country. This includes transforming mental health services into neighbourhood mental health centres open 24 hours a day, seven days a week, improving assertive outreach, expanding talking therapies and giving patients better access to all-hours support directly through the NHS App.
Asked by: Carla Lockhart (Democratic Unionist Party - Upper Bann)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help improve the availability of clinical trials for cancer patients across the UK.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is committed to ensuring that all patients, including those with cancer, have access to cutting-edge clinical trials and innovative, lifesaving treatments.
The Department funds research and research infrastructure through the National Institute for Health and Care Research (NIHR), which supports National Health Service patients, the public, and NHS organisations across England to participate in high-quality research, including clinical trials into cancers.
The NIHR provides an online service called 'Be Part of Research', which promotes participation in health and social care research by allowing users to search for relevant studies, including those with cancer, and register their interest.
NHS England is delivering The NHS Cancer Vaccine Launch Pad, a platform that is speeding up access to clinical trials for cancer vaccines and immunotherapies for patients who have been diagnosed with cancer.
The forthcoming National Cancer Plan will include further details on how we will improve outcomes for cancer patients across the country. It will ensure that more patients have access to the latest treatments and technology, and to clinical trials.
The Government also supports the Rare Cancers Private Members Bill. The bill will make it easier for clinical trials, on for example pancreatic cancer, to take place in England, by ensuring the patient population can be more easily contacted by researchers.
Asked by: Carla Lockhart (Democratic Unionist Party - Upper Bann)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what plans his Department has to encourage collaboration between NHS Trusts and pharmaceutical companies to enhance cancer clinical trials.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is committed to ensuring that all patients, including those with cancer, have access to cutting-edge clinical trials and innovative, lifesaving treatments.
We are incentivising clinical trials and strengthening collaboration between pharmaceutical companies and National Health Service trusts by streamlining processes and cutting set‑up times to 150 days by March 2026, ensuring the United Kingdom offers a faster, more competitive environment for delivering high‑quality research.
The Department funded National Institute of Health and Care Research (NIHR) funds research and research infrastructure which supports patients and the public to participate in high-quality research. This includes Experimental Cancer Medicine Centres, co-funded by NIHR, Cancer Research UK, and the Little Princess Trust, which form a UK-wide network that brings together world leading laboratory and clinical researchers to deliver pioneering early phase cancer trials for adults and children. Additionally, the Medicines and Healthcare products Regulatory Agency will introduce a 14-day assessment route for phase 1 trials, adopting an innovative stepwise approach, restoring a rapid pathway for the earliest testing of new medicines in people, a key draw for global pharmaceutical companies deciding where to base their research.
NHS England is delivering specific collaborative initiatives with industry such as the Cancer Vaccine Launch Pad (CVLP). The NHS CVLP is a platform that is speeding up access to clinical trials for cancer vaccines and immunotherapies for patients who have been diagnosed with cancer. The CVLP platform is designed to be company and clinical trial agnostic. Different companies have been involved in the CVLP and trials in the CVLP portfolio have included cancers such as head and neck cancer melanoma and colorectal cancer.
35 Commercial Research Delivery Centres (CRDCs), including primary care been established largely within NHS trusts. CRDCs will expand capacity, streamline set-up, and give patients faster access to innovative treatments and clinical trials, including those concerning cancer.
Asked by: Carla Lockhart (Democratic Unionist Party - Upper Bann)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impacts of the decriminalisation of abortion on (a) clinical safeguards, (b) informed consent procedures, (c) access to alternative support services, and (d) the protection of vulnerable women.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The House of Commons has voted to add a clause to the Crime and Policing Bill which disapplies the criminal offences related to abortion for a woman acting in relation to her own pregnancy. These offences would still apply to medical professionals and third parties who do not abide by the rules set out in the Abortion Act 1967. The bill will now continue its progress through Parliament.
Informed consent is separate from the requirements set by the Abortion Act for two doctors to certify that a woman meets the grounds for abortion. Consent to treatment means a person must give permission before they receive any type of medical treatment, test, or examination. For consent to be valid, it must be voluntary and informed, and the person consenting must have the capacity to make the decision. These principles will continue to apply irrespective of whether abortion is decriminalised.
As part of standards set by the Care Quality Commission, abortion services must be able to prove that they have processes in place to ensure that all women and girls are seeking services voluntarily. It will also remain a requirement for an abortion service, as laid out in the Department’s Required Standard Operating Procedures, that staff should be able to identify those who require more support than can be provided in the routine abortion service setting, including where there is evidence of coercion.
Safeguarding is an essential aspect of abortion care, and abortion providers are required to have effective arrangements in place to safeguard children and vulnerable adults accessing their services. Providers must ensure that all staff are trained to recognise the signs of potential abuse and coercion and know how to respond. In addition, we expect all providers to have due regard to the Royal College of Paediatrics and Child Health’s national safeguarding guidance for under-18 year olds accessing early medical abortion services.
The Department is continuing to monitor abortion related amendments to the Crime and Policing Bill and will consider whether current arrangements are sufficient or if additional guidance is needed.
Asked by: Carla Lockhart (Democratic Unionist Party - Upper Bann)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will take steps to ensure that women considering abortion are provided with comprehensive information on all available options, including parenting, adoption, and perinatal palliative care.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
In line with the Department’s required standard operating procedures for the approval of independent sector places for termination of pregnancy in England, women seeking abortion services must be given impartial, accurate, and evidence-based information so that they are able to make an informed choice about their preferred course of action.
The National Health Service website provides factual information on abortion, including directing people seeking impartial information and support to their general practice or to regulated organisations such as Brook, for under 25 year olds, the British Pregnancy Advisory Service, MSI Reproductive Health Choices UK, and National Unplanned Pregnancy Advisory Service. All the main abortion providers offer pregnancy counselling, which includes advice on options such as parenting and adoption.
Following a diagnosis of fetal anomaly, women and their partners must receive appropriate counselling and support. At no stage should there be a bias towards abortion. All staff involved in the care of a woman or couple facing a possible termination of pregnancy must adopt a nondirective, non-judgemental, and supportive approach. It should not be assumed that a woman will choose to have a termination, and a decision to continue with the pregnancy must be fully supported. In addition, the charity Antenatal Results and Choices offers information and support for people who have received a diagnosis after antenatal screening.
Asked by: Carla Lockhart (Democratic Unionist Party - Upper Bann)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has plans to review the scope of statutory protections for healthcare professionals who conscientiously object to participating in abortion procedures.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
There are no plans to review the scope of statutory protections for healthcare professionals who conscientiously object to participating in abortion procedures. In England and Wales the right to refuse to participate in terminations of pregnancy, other than where the termination is necessary to save the life of, or prevent grave injury to, the pregnant woman, is protected by law under section 4(1) of the Abortion Act 1967.
Asked by: Carla Lockhart (Democratic Unionist Party - Upper Bann)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department plans to review the 24-week abortion gestational limit in light of recent scientific evidence on foetal pain and advances in neonatal care.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
There are no plans for the Government to review the gestational limits of abortion. It is for Parliament to decide whether to make any changes to the law on abortion, including gestational time limits.
When the time limit was last reduced in 1990, there was a clear consensus from the medical profession that the age of viability had reduced from 28 weeks to 24 weeks gestation. There is currently no clear medical consensus that the age of viability has reduced below 24 weeks.
The Government does not formulate policy on fetal sentience and fetal pain. The review and determination of fetal sentience and its implications for abortion and clinical practice is reached through professional medical consensus and clinical guidance.
The Royal College of Obstetricians and Gynaecologists has carried out a comprehensive review into fetal awareness evidence. Published in December 2022, the review concluded that the evidence to date indicates that the possibility of pain perception before 28 weeks of gestation is unlikely.
Asked by: Carla Lockhart (Democratic Unionist Party - Upper Bann)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what guidance his Department issues to abortion providers on informing women of alternative support services and pathways before an abortion is undertaken.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department’s required standard operating procedures for the approval of independent sector places for termination of pregnancy, or abortion, in England sets out that women requesting termination of pregnancy must be given impartial, accurate, and evidence-based information, both verbal and written, delivered in a clear, understandable, and non-judgemental way. This includes informing women about their options so that they can make an informed choice about their preferred course of action. As early as possible, women should be provided with detailed information including alternatives to abortions, for instance, adoption and motherhood. Their choice should be respected without any unnecessary delay.
Asked by: Carla Lockhart (Democratic Unionist Party - Upper Bann)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of whether abortion providers, including British Pregnancy Advisory Service and Marie Stopes InternationaI Reproductive Choices, provide clear and comprehensive information to pregnant women on the full range of childcare and maternity related financial support available to them.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department’s required standard operating procedures for the approval of independent sector places for the termination of a pregnancy, an abortion, in England sets out that women requesting termination of pregnancy must be given impartial, accurate, and evidence-based information, both verbal and written, delivered in a clear, understandable, and non-judgemental way. This includes informing women about their options so that they can make an informed choice about their preferred course of action. As early as possible, women should be provided with detailed information, including on alternatives to abortions such as adoption and motherhood. Their choice should be respected without any unnecessary delay.
Asked by: Carla Lockhart (Democratic Unionist Party - Upper Bann)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that patients have timely access to innovative cancer medicines.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
In England, the National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether new licensed medicines should be routinely funded by the NHS based on an assessment of clinical and cost effectiveness. The NHS is legally required to fund NICE recommended medicines, normally within three months of final guidance, and cancer medicines are eligible for funding from the point of a positive draft NICE recommendation. NICE aims wherever possible to issue guidance on new medicines close to the time of licensing to ensure that patients are able to benefit from rapid access to clinically and cost effective new medicines.
The Life Sciences Sector Plan sets out the measures we are taking that will mean that patients are able to access medicines three to six months faster, including improved alignment between the Medicines and Healthcare products Regulatory Agency’s decisions and NICE guidance publication.
In England in 2024/25, 93% of NICE recommendations for cancer treatments were positive. Positive includes recommended, optimised, recommended in the cancer drugs fund (CDF), and optimised in the CDF.
Health is a devolved matter and as such it would not be appropriate for me to comment on access to medicines within the devolved administrations.